It is being reported that 2 phase III clinical trials are set to begin using Schering-Plough's HIV drug Vicriviroc, which is given to patients who have stopped responding to other treatments
It is being reported that an HIV drug manufactured by Schering-Plough is entering in to a phase 3 clinical trial.
Two phase 3 clinical trials are underway for vicriviroc, which is taken once daily and is used to treat HIV patients whose virus has stopped responding to other drug therapies.
Each of the clinical trials is featuring 375 participants. Both trials follow a 48 week study in which vicriviroc showed "potent and sustained viral suppression" in patients not responding to other treatments.
There are some noted safety issues with the drug, as cases of cancer have been reported in study participants.
"As a next-generation HIV entry inhibitor, vicriviroc has the potential to benefit a broad range of patients by offering a potent, sustained viral response and a single once-daily dose in combination with optimized background therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "There is an urgent need for new antiretroviral agents with novel mechanisms of action and we look forward to the further clinical evaluation of vicriviroc in these large global studies."
No comments:
Post a Comment